Sequencing ALK inhibitors: alectinib in crizotinib-resistant patients, a phase 2 trial by Shaw et al

Affiliations

Editorial

Laura Mezquita et al. J Thorac Dis. 2016 Nov.

. 2016 Nov;8(11):2997-3002.

doi: 10.21037/jtd.2016.11.76.

¹ Gustave Roussy Cancer Campus, 114 Rue Edouard Vaillant, 94805 Villejuif, France.

No abstract available

Conflict of interest statement

The authors have no conflicts of interest to declare.

Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial.
Shaw AT, Gandhi L, Gadgeel S, Riely GJ, Cetnar J, West H, Camidge DR, Socinski MA, Chiappori A, Mekhail T, Chao BH, Borghaei H, Gold KA, Zeaiter A, Bordogna W, Balas B, Puig O, Henschel V, Ou SI; study investigators. Shaw AT, et al. Lancet Oncol. 2016 Feb;17(2):234-242. doi: 10.1016/S1470-2045(15)00488-X. Epub 2015 Dec 19. Lancet Oncol. 2016. PMID: 26708155 Free PMC article. Clinical Trial.

1. Sullivan I, Planchard D. Treatment modalities for advanced ALK-rearranged non-small-cell lung cancer. Future Oncol 2016;12:945-61. 10.2217/fon.16.15 - DOI - PubMed
1. Seto T, Kiura K, Nishio M, et al. CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study. Lancet Oncol 2013;14:590-8. 10.1016/S1470-2045(13)70142-6 - DOI - PubMed
1. Gadgeel SM, Gandhi L, Riely GJ, et al. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study. Lancet Oncol 2014;15:1119-28. 10.1016/S1470-2045(14)70362-6 - DOI - PubMed
1. Shaw AT, Gandhi L, Gadgeel S, et al. Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial. Lancet Oncol 2016;17:234-42. 10.1016/S1470-2045(15)00488-X - DOI - PMC - PubMed
1. Kim DW, Ahn MJ, Shi Y, et al. Results of a global phase II study with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC). J Clin Oncol 2012;30:abstr 7533.